Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTA30X UCAR-T in r/r CD19+ B Hematologic Malignancies
NCT05015972Phase 1Withdrawn
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cta-30x in acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Primary endpoints: Dose Limiting Toxicity at 24 weeks and Incidence of Adverse Events at 4 weeks. Planned start Aug 2021; status: withdrawn.
02
Drugs
cta-30x
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT05015972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015972.